News

New study looks at use of Riluzole to slow Alzheimer's progression

Published Date:

Riluzole is an FDA-approved drug, currently used to treat amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and is currently in a Phase II clinical trial for the treatment of mild Alzheimer’s disease (AD) (Clinical Trial #NCT01703117). The exact reason behind riluzole’s potential benefits on cognition in AD patients is unknown. One potential way may be through altering glutamate signaling in the brain, a neurotransmitter essential for learning and memory.

A team of researchers at the Center for Alzheimer’s Disease and Related Disorders at SIU Medicine lead by Kevin N. Hascup, PhD, and Erin R. Hascup, PhD, recently published a study in the Journal of Neurochemistry with the intent to determine the long-term therapeutic benefits of early riluzole treatment in the AβPP/PS1 mouse model of Alzheimer’s disease. The researchers determined that early intervention with riluzole was able to restore a specific type of communication between cells in the brain, glutamatergic neurotransmission, and delay or prevent learning and memory deficits associated with Alzheimer’s disease.

Overall, the results of this study lend further support of the use of riluzole as an early therapeutic intervention strategy to delay or prevent cognitive decline and restore the way cells communicate in the brain.

More from SIU News

White Coat group Class of 2029

Class of 2029 - SIU School of Medicine

Student roster with hometowns & family, listed by region
COVID Stories Save the Dates

Audition to tell ‘COVID Stories’

University of Illinois Springfield and SIU School of Medicine are partnering to present "COVID Stories," a reader’s theater using real interviews about local Illinois residents’ pandemic experiences.
Dr. Ruchika Goel & Dr. O.H. Wesly

Dr. Ruchika Goel honored with endowed chair in hematologic disorders

Dr. Ruchika Goel is the inaugural recipient of the O.H. Wesly Endowed Chair of Excellence in Hematologic Disorders. The investiture ceremony on August 26 honored both Goel’s remarkable career as a physician-scientist and the enduring legacy of Dr. Wesly, whose generosity made the endowment possible.